I1887
インダパミド
analytical standard, for drug analysis
別名:
N-(4-クロロ-3-スルファモイルベンズアミド)-2-メチルインドリン
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C16H16ClN3O3S
CAS番号:
分子量:
365.83
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
248-012-7
MDL number:
Quality Level
technique(s)
gas chromatography (GC): suitable, HPLC: suitable
application(s)
forensics and toxicology
pharmaceutical (small molecule)
veterinary
format
neat
SMILES string
CC1Cc2ccccc2N1NC(=O)c3ccc(Cl)c(c3)S(N)(=O)=O
InChI
1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
InChI key
NDDAHWYSQHTHNT-UHFFFAOYSA-N
Gene Information
human ... SLC12A3(6559)
General description
Indapamide is a deuretic drug, belonging to the class of benzothiadiazines. It is commonly used for the treatment of hypertension. The drug acts by causing a drop in systolic, diastolic and mean blood pressure.
Application
Indapamide may be used as an internal standard for the quantification of the analyte in pharmaceutical formulations and biological samples using different analytical techniques
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Still not finding the right product?
Explore all of our products under インダパミド
signalword
Warning
hcodes
Hazard Classifications
Lact. - Repr. 2
保管分類
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
A selective HPLC method for the determination of indapamide in human whole blood: Application to a bioequivalence study in Chinese volunteers
Hang J-T, et al.
Journal of Pharmaceutical and Biomedical Analysis, 40(1), 202-205 (2006)
N Beckett et al.
BMJ (Clinical research ed.), 344, d7541-d7541 (2012-01-06)
To assess if very elderly people with hypertension obtain early benefit from antihypertensive treatment. One year open label active treatment extension of randomised controlled trial (Hypertension in the Very Elderly Trial (HYVET)). Hospital and general practice based centres mainly in
Susan van Dieren et al.
Diabetes research and clinical practice, 98(1), 83-90 (2012-06-09)
To asses differences in treatment effects of a fixed combination of perindopril-indapamide on major clinical outcomes in patients with type 2 diabetes across subgroups of cardiovascular risk. 11,140 participants with type 2 diabetes, from the ADVANCE trial, were randomized to